AstraZeneca Had Record Approvals in Past Year: Hudson

March 20 -- Paul Hudson, president of AstraZeneca U.S. and executive vice president of AstraZeneca North America, talks about the drug-maker's Brilinta blood-thinning medicine, research and development, and AstraZeneca Plc's decision to reject a $117 billion offer from Pfizer Inc. Hudson, speaking with Stephanie Ruhle and Bill Cohan on Bloomberg Television's "Market Makers," also discusses the impact of the U.S. dollar and Obamacare on the company, and the process of naming new drugs. (Source: Bloomberg)

Full Show: What'd You Miss? (08/07)
06:30 - Guests include: BorgWarner CEO James Verrier, Amherst Pierpont's Robert Sinche and Ritholtz Wealth Management's Ben Carlson. (Source: Bloomberg)
  • QuickTake: Active vs. Passive Investing
  • Molson Coors' Canadian Business Challenges
  • Why Adidas Is Crushing the Competition